High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Valuation Metrics
The current forward P/E ratio for InterCure Ltd (INCR.O) is 0.00, compared to its 5-year average forward P/E of -0.38. For a more detailed relative valuation and DCF analysis to assess InterCure Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.38
Current PE
0.00
Overvalued PE
0.79
Undervalued PE
-1.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.31
Current EV/EBITDA
1.09
Overvalued EV/EBITDA
12.51
Undervalued EV/EBITDA
-11.89
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.44
Current PS
0.00
Overvalued PS
2.52
Undervalued PS
0.36
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
INCR News & Events
Events Timeline
(ET)
2025-11-03
08:38:59
InterCure and Cannasoul Forge Strategic Investment and Collaboration Partnerships
2025-10-08 (ET)
2025-10-08
09:03:28
InterCure Announces 1H Revenue of NIS 130M, Up from NIS 126M Last Year
2025-09-19 (ET)
2025-09-19
08:51:16
InterCure Reveals Purchase of ISHI for 4.92 Million Common Shares
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/45d4bd4846f9ec3ad6e72181c53f581e15a7dc1b9fba9249b56b834b3920c131.png)
Preview
8.5
09-19BenzingaInterCure Joins High-End US Cannabis Market Through ISHI Agreement
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
8.5
09-19NewsfilterInterCure Reveals Strategic Purchase of ISHI, Gaining Access to Top U.S. Cannabis Technology and Brands
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/markets.png)
Preview
5.0
02-13Business InsiderInterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak
Sign Up For More News
People Also Watch
FAQ
What is InterCure Ltd (INCR) stock price today?
What is InterCure Ltd (INCR)'s business?
What is the price predicton of INCR Stock?
What is InterCure Ltd (INCR)'s revenue for the last quarter?
What is InterCure Ltd (INCR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for InterCure Ltd (INCR)'s fundamentals?
How many employees does InterCure Ltd (INCR). have?